Cargando…
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Nucleic acid therapeutics are developing into precise medicines that can manipulate specific genes. However, the development of safe and effective delivery system for the target cells has remained a challenge. Lipid nanoparticles (LNPs) have provided a revolutionary delivery system that can ensure m...
Autores principales: | Suzuki, Yuta, Ishihara, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502116/ https://www.ncbi.nlm.nih.gov/pubmed/34757287 http://dx.doi.org/10.1016/j.dmpk.2021.100424 |
Ejemplares similares
-
Irf5 siRNA-loaded biodegradable lipid nanoparticles ameliorate concanavalin A-induced liver injury
por: Kawase, Wataru, et al.
Publicado: (2021) -
Advances in Lipid Nanoparticles for siRNA Delivery
por: Tam, Yuen Yi C., et al.
Publicado: (2013) -
Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)
por: Adams, David, et al.
Publicado: (2015) -
Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection
por: Kon, Edo, et al.
Publicado: (2020) -
Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)